Abstract
The incidence of multiple myeloma (MM) has increased in the last 20 years, particularly in middle and low-middle income countries. Access to diagnostic and prognostic tests and the availability of effective care is highly variable globally. Latin America represents 10% of the world population, distributed in countries of varied size, population, and socio-economic development. In the last decade, great improvements have been made in the diagnosis and treatment of MM. Applying these advances in real life is a challenge in our region. Local data regarding MM standards of care and outcomes are limited. A survey was carried out among hematologists from 15 Latin American countries to describe access to MM diagnostic and prognostic tests and the availability of effective care options. This study provides real-world data for MM in our region, highlighting striking differences between public and private access to essential analyses and therapeutic options.
Similar content being viewed by others
References
Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, Foreman K, Gupta R, Harvey J, Hosgood HD, Jakovljevic M, Khader Y, Linn S, Lad D, Mantovani L, Nong VM, Mokdad A, Naghavi M, Postma M, Roshandel G, Shackelford K, Sisay M, Nguyen CT, Tran TT, Xuan BT, Ukwaja KN, Vollset SE, Weiderpass E, Libby EN, Fitzmaurice C (2018) Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol 4(9):1221–1227. https://doi.org/10.1001/jamaoncol.2018.2128
Curado MP, Oliveira MM, Silva DRM, Souza DLB (2018 May) Epidemiology of multiple myeloma in 17 Latin American countries: an update. Cancer Med 7(5):2101–2108
Social Development Division and the Statistics and Economic Projections Division of the Economic Commission for Latin America and the Caribbean (ECLAC). ECLAC Annual Review, 2010. Social panorama of Latin America. http://www.eclac.org/publicaciones/xml/1/41801/PSI-socialpanorama2010.pdf
Gabús R, Galeano S, de Souza CA, Howard S, Milone JH, Valle ML et al (2011) Hematology in Latin America: where are we? Analysis of the reports of Societies of Hematology associated organization of the Highlights of ASH in Latin America. Rev Bras Hematol Hemoter 33(6):449–454
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G (2014 Nov) Mateos MV, et al International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15(12):e538–e548
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al (2016 Aug) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346
Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ, Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013 Apr;88(4):360–76
Hungria VT, Maiolino A, Martinez G, Duarte GO, Bittencourt R, Peters L et al (2017) Observational study of multiple myeloma in Latin America. Ann Hematol 96:65–72
Gale RP, Seber A, Bonfim C, Pasquini M (2016 Jul) Haematopoietic cell transplants in Latin America. Bone Marrow Transplant 51(7):898–905
Tarín-Arzaga L, Arredondo-Campos D, Martínez-Pacheco V, Martínez-González O, Ramírez-López A, Gómez-De León A, Gutiérrez- Aguirre CH, Cantú-Rodríguez O, Jaime-Pérez JC, Gómez-Almaguer D. Impact of the affordability of new agents in patients with multiple myeloma: real-world data of current clinical practice in Mexico, Cancer 2018 May 1; 124 ( 9): 1946–1953
Acknowledgments
The authors thank all members of GELAMM and colleagues from Latin America that participated in the survey. The authors thank Dr. J. L Harousseau and Dr. J. R. Mikhael for their contribution to the critical revision.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical approval
Ethical approvals were obtained at each participating institution.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOCX 17 kb)
Rights and permissions
About this article
Cite this article
Riva, E., Schütz, N., Peña, C. et al. Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results of a Latin American survey. GELAMM (Grupo de Estudio Latino Americano de Mieloma Múltiple). Ann Hematol 99, 1025–1030 (2020). https://doi.org/10.1007/s00277-020-03983-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-020-03983-x